Hmdb loader
Survey
You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on Human Metabolome Database.
Record Information
Version5.0
StatusDetected but not Quantified
Creation Date2021-09-11 10:42:06 UTC
Update Date2021-09-26 23:05:28 UTC
HMDB IDHMDB0252717
Secondary Accession NumbersNone
Metabolite Identification
Common NameGilteritinib
DescriptionGilteritinib, also known as asp 2215 or xospata, belongs to the class of organic compounds known as diphenylmethanes. Diphenylmethanes are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups. Based on a literature review a significant number of articles have been published on Gilteritinib. This compound has been identified in human blood as reported by (PMID: 31557052 ). Gilteritinib is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Gilteritinib is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources.
Structure
Thumb
Synonyms
ValueSource
6-Ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)-2-pyrazinecarboxamideChEBI
6-Ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-2-carboxamideChEBI
ASP 2215ChEBI
ASP-2215ChEBI
ASP2215ChEBI
GilteritinibumChEBI
XospataChEBI
ASP-2215asp2215ChEMBL
Chemical FormulaC29H44N8O3
Average Molecular Weight552.724
Monoisotopic Molecular Weight552.353637309
IUPAC Name6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide
Traditional Name6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(oxan-4-ylamino)pyrazine-2-carboxamide
CAS Registry NumberNot Available
SMILES
CCC1=C(NC2CCOCC2)N=C(NC2=CC=C(N3CCC(CC3)N3CCN(C)CC3)C(OC)=C2)C(=N1)C(N)=O
InChI Identifier
InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)
InChI KeyGYQYAJJFPNQOOW-UHFFFAOYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as diphenylmethanes. Diphenylmethanes are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Phenylpropane
  • Phenoxy compound
  • Phenol ether
  • Alkyl aryl ether
  • Ether
  • Organic oxygen compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Ontology
Physiological effectNot Available
Disposition
ProcessNot Available
RoleNot Available
Physical Properties
StateNot Available
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
logP3.51ALOGPS
logP2.79ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)14.21ChemAxon
pKa (Strongest Basic)8.47ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area121.11 ŲChemAxon
Rotatable Bond Count9ChemAxon
Refractivity159.84 m³·mol⁻¹ChemAxon
Polarizability62.92 ųChemAxon
Number of Rings5ChemAxon
BioavailabilityYesChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DeepCCS[M+H]+227.5930932474
DeepCCS[M-H]-225.19430932474
DeepCCS[M-2H]-258.30630932474
DeepCCS[M+Na]+233.51730932474
AllCCS[M+H]+230.932859911
AllCCS[M+H-H2O]+229.732859911
AllCCS[M+NH4]+231.932859911
AllCCS[M+Na]+232.232859911
AllCCS[M-H]-208.732859911
AllCCS[M+Na-2H]-211.232859911
AllCCS[M+HCOO]-214.032859911

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
GilteritinibCCC1=C(NC2CCOCC2)N=C(NC2=CC=C(N3CCC(CC3)N3CCN(C)CC3)C(OC)=C2)C(=N1)C(N)=O3875.9Standard polar33892256
GilteritinibCCC1=C(NC2CCOCC2)N=C(NC2=CC=C(N3CCC(CC3)N3CCN(C)CC3)C(OC)=C2)C(=N1)C(N)=O4516.4Standard non polar33892256
GilteritinibCCC1=C(NC2CCOCC2)N=C(NC2=CC=C(N3CCC(CC3)N3CCN(C)CC3)C(OC)=C2)C(=N1)C(N)=O4955.4Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Gilteritinib,1TMS,isomer #1CCC1=NC(C(=O)N[Si](C)(C)C)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1NC1CCOCC14798.7Semi standard non polar33892256
Gilteritinib,1TMS,isomer #1CCC1=NC(C(=O)N[Si](C)(C)C)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1NC1CCOCC14429.5Standard non polar33892256
Gilteritinib,1TMS,isomer #1CCC1=NC(C(=O)N[Si](C)(C)C)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1NC1CCOCC17265.9Standard polar33892256
Gilteritinib,1TMS,isomer #2CCC1=NC(C(N)=O)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1N(C1CCOCC1)[Si](C)(C)C4706.4Semi standard non polar33892256
Gilteritinib,1TMS,isomer #2CCC1=NC(C(N)=O)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1N(C1CCOCC1)[Si](C)(C)C4262.2Standard non polar33892256
Gilteritinib,1TMS,isomer #2CCC1=NC(C(N)=O)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1N(C1CCOCC1)[Si](C)(C)C7354.8Standard polar33892256
Gilteritinib,1TMS,isomer #3CCC1=NC(C(N)=O)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C)N=C1NC1CCOCC14695.8Semi standard non polar33892256
Gilteritinib,1TMS,isomer #3CCC1=NC(C(N)=O)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C)N=C1NC1CCOCC14214.6Standard non polar33892256
Gilteritinib,1TMS,isomer #3CCC1=NC(C(N)=O)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C)N=C1NC1CCOCC17232.8Standard polar33892256
Gilteritinib,2TMS,isomer #1CCC1=NC(C(=O)N([Si](C)(C)C)[Si](C)(C)C)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1NC1CCOCC14771.4Semi standard non polar33892256
Gilteritinib,2TMS,isomer #1CCC1=NC(C(=O)N([Si](C)(C)C)[Si](C)(C)C)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1NC1CCOCC14543.6Standard non polar33892256
Gilteritinib,2TMS,isomer #1CCC1=NC(C(=O)N([Si](C)(C)C)[Si](C)(C)C)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1NC1CCOCC16970.6Standard polar33892256
Gilteritinib,2TMS,isomer #2CCC1=NC(C(=O)N[Si](C)(C)C)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C)N=C1NC1CCOCC14626.5Semi standard non polar33892256
Gilteritinib,2TMS,isomer #2CCC1=NC(C(=O)N[Si](C)(C)C)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C)N=C1NC1CCOCC14339.3Standard non polar33892256
Gilteritinib,2TMS,isomer #2CCC1=NC(C(=O)N[Si](C)(C)C)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C)N=C1NC1CCOCC16807.1Standard polar33892256
Gilteritinib,2TMS,isomer #3CCC1=NC(C(=O)N[Si](C)(C)C)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1N(C1CCOCC1)[Si](C)(C)C4632.7Semi standard non polar33892256
Gilteritinib,2TMS,isomer #3CCC1=NC(C(=O)N[Si](C)(C)C)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1N(C1CCOCC1)[Si](C)(C)C4378.3Standard non polar33892256
Gilteritinib,2TMS,isomer #3CCC1=NC(C(=O)N[Si](C)(C)C)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1N(C1CCOCC1)[Si](C)(C)C6898.7Standard polar33892256
Gilteritinib,2TMS,isomer #4CCC1=NC(C(N)=O)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C)N=C1N(C1CCOCC1)[Si](C)(C)C4538.9Semi standard non polar33892256
Gilteritinib,2TMS,isomer #4CCC1=NC(C(N)=O)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C)N=C1N(C1CCOCC1)[Si](C)(C)C4215.7Standard non polar33892256
Gilteritinib,2TMS,isomer #4CCC1=NC(C(N)=O)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C)N=C1N(C1CCOCC1)[Si](C)(C)C6959.6Standard polar33892256
Gilteritinib,3TMS,isomer #1CCC1=NC(C(=O)N([Si](C)(C)C)[Si](C)(C)C)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C)N=C1NC1CCOCC14644.6Semi standard non polar33892256
Gilteritinib,3TMS,isomer #1CCC1=NC(C(=O)N([Si](C)(C)C)[Si](C)(C)C)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C)N=C1NC1CCOCC14418.2Standard non polar33892256
Gilteritinib,3TMS,isomer #1CCC1=NC(C(=O)N([Si](C)(C)C)[Si](C)(C)C)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C)N=C1NC1CCOCC16413.0Standard polar33892256
Gilteritinib,3TMS,isomer #2CCC1=NC(C(=O)N([Si](C)(C)C)[Si](C)(C)C)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1N(C1CCOCC1)[Si](C)(C)C4670.6Semi standard non polar33892256
Gilteritinib,3TMS,isomer #2CCC1=NC(C(=O)N([Si](C)(C)C)[Si](C)(C)C)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1N(C1CCOCC1)[Si](C)(C)C4484.2Standard non polar33892256
Gilteritinib,3TMS,isomer #2CCC1=NC(C(=O)N([Si](C)(C)C)[Si](C)(C)C)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1N(C1CCOCC1)[Si](C)(C)C6497.3Standard polar33892256
Gilteritinib,3TMS,isomer #3CCC1=NC(C(=O)N[Si](C)(C)C)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C)N=C1N(C1CCOCC1)[Si](C)(C)C4525.8Semi standard non polar33892256
Gilteritinib,3TMS,isomer #3CCC1=NC(C(=O)N[Si](C)(C)C)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C)N=C1N(C1CCOCC1)[Si](C)(C)C4307.9Standard non polar33892256
Gilteritinib,3TMS,isomer #3CCC1=NC(C(=O)N[Si](C)(C)C)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C)N=C1N(C1CCOCC1)[Si](C)(C)C6334.1Standard polar33892256
Gilteritinib,4TMS,isomer #1CCC1=NC(C(=O)N([Si](C)(C)C)[Si](C)(C)C)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C)N=C1N(C1CCOCC1)[Si](C)(C)C4604.8Semi standard non polar33892256
Gilteritinib,4TMS,isomer #1CCC1=NC(C(=O)N([Si](C)(C)C)[Si](C)(C)C)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C)N=C1N(C1CCOCC1)[Si](C)(C)C4375.5Standard non polar33892256
Gilteritinib,4TMS,isomer #1CCC1=NC(C(=O)N([Si](C)(C)C)[Si](C)(C)C)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C)N=C1N(C1CCOCC1)[Si](C)(C)C5868.4Standard polar33892256
Gilteritinib,1TBDMS,isomer #1CCC1=NC(C(=O)N[Si](C)(C)C(C)(C)C)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1NC1CCOCC14969.5Semi standard non polar33892256
Gilteritinib,1TBDMS,isomer #1CCC1=NC(C(=O)N[Si](C)(C)C(C)(C)C)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1NC1CCOCC14606.2Standard non polar33892256
Gilteritinib,1TBDMS,isomer #1CCC1=NC(C(=O)N[Si](C)(C)C(C)(C)C)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1NC1CCOCC17211.0Standard polar33892256
Gilteritinib,1TBDMS,isomer #2CCC1=NC(C(N)=O)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1N(C1CCOCC1)[Si](C)(C)C(C)(C)C4896.2Semi standard non polar33892256
Gilteritinib,1TBDMS,isomer #2CCC1=NC(C(N)=O)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1N(C1CCOCC1)[Si](C)(C)C(C)(C)C4454.9Standard non polar33892256
Gilteritinib,1TBDMS,isomer #2CCC1=NC(C(N)=O)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1N(C1CCOCC1)[Si](C)(C)C(C)(C)C7300.3Standard polar33892256
Gilteritinib,1TBDMS,isomer #3CCC1=NC(C(N)=O)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C(C)(C)C)N=C1NC1CCOCC14865.2Semi standard non polar33892256
Gilteritinib,1TBDMS,isomer #3CCC1=NC(C(N)=O)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C(C)(C)C)N=C1NC1CCOCC14375.4Standard non polar33892256
Gilteritinib,1TBDMS,isomer #3CCC1=NC(C(N)=O)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C(C)(C)C)N=C1NC1CCOCC17183.6Standard polar33892256
Gilteritinib,2TBDMS,isomer #1CCC1=NC(C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1NC1CCOCC15126.6Semi standard non polar33892256
Gilteritinib,2TBDMS,isomer #1CCC1=NC(C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1NC1CCOCC14875.3Standard non polar33892256
Gilteritinib,2TBDMS,isomer #1CCC1=NC(C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1NC1CCOCC16903.2Standard polar33892256
Gilteritinib,2TBDMS,isomer #2CCC1=NC(C(=O)N[Si](C)(C)C(C)(C)C)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C(C)(C)C)N=C1NC1CCOCC14925.8Semi standard non polar33892256
Gilteritinib,2TBDMS,isomer #2CCC1=NC(C(=O)N[Si](C)(C)C(C)(C)C)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C(C)(C)C)N=C1NC1CCOCC14651.0Standard non polar33892256
Gilteritinib,2TBDMS,isomer #2CCC1=NC(C(=O)N[Si](C)(C)C(C)(C)C)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C(C)(C)C)N=C1NC1CCOCC16712.7Standard polar33892256
Gilteritinib,2TBDMS,isomer #3CCC1=NC(C(=O)N[Si](C)(C)C(C)(C)C)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1N(C1CCOCC1)[Si](C)(C)C(C)(C)C4941.9Semi standard non polar33892256
Gilteritinib,2TBDMS,isomer #3CCC1=NC(C(=O)N[Si](C)(C)C(C)(C)C)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1N(C1CCOCC1)[Si](C)(C)C(C)(C)C4723.6Standard non polar33892256
Gilteritinib,2TBDMS,isomer #3CCC1=NC(C(=O)N[Si](C)(C)C(C)(C)C)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1N(C1CCOCC1)[Si](C)(C)C(C)(C)C6803.4Standard polar33892256
Gilteritinib,2TBDMS,isomer #4CCC1=NC(C(N)=O)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C(C)(C)C)N=C1N(C1CCOCC1)[Si](C)(C)C(C)(C)C4897.2Semi standard non polar33892256
Gilteritinib,2TBDMS,isomer #4CCC1=NC(C(N)=O)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C(C)(C)C)N=C1N(C1CCOCC1)[Si](C)(C)C(C)(C)C4547.4Standard non polar33892256
Gilteritinib,2TBDMS,isomer #4CCC1=NC(C(N)=O)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C(C)(C)C)N=C1N(C1CCOCC1)[Si](C)(C)C(C)(C)C6829.0Standard polar33892256
Gilteritinib,3TBDMS,isomer #1CCC1=NC(C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C(C)(C)C)N=C1NC1CCOCC15111.8Semi standard non polar33892256
Gilteritinib,3TBDMS,isomer #1CCC1=NC(C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C(C)(C)C)N=C1NC1CCOCC14886.2Standard non polar33892256
Gilteritinib,3TBDMS,isomer #1CCC1=NC(C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C(C)(C)C)N=C1NC1CCOCC16304.6Standard polar33892256
Gilteritinib,3TBDMS,isomer #2CCC1=NC(C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1N(C1CCOCC1)[Si](C)(C)C(C)(C)C5139.8Semi standard non polar33892256
Gilteritinib,3TBDMS,isomer #2CCC1=NC(C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1N(C1CCOCC1)[Si](C)(C)C(C)(C)C4982.5Standard non polar33892256
Gilteritinib,3TBDMS,isomer #2CCC1=NC(C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1N(C1CCOCC1)[Si](C)(C)C(C)(C)C6383.2Standard polar33892256
Gilteritinib,3TBDMS,isomer #3CCC1=NC(C(=O)N[Si](C)(C)C(C)(C)C)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C(C)(C)C)N=C1N(C1CCOCC1)[Si](C)(C)C(C)(C)C4988.2Semi standard non polar33892256
Gilteritinib,3TBDMS,isomer #3CCC1=NC(C(=O)N[Si](C)(C)C(C)(C)C)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C(C)(C)C)N=C1N(C1CCOCC1)[Si](C)(C)C(C)(C)C4774.1Standard non polar33892256
Gilteritinib,3TBDMS,isomer #3CCC1=NC(C(=O)N[Si](C)(C)C(C)(C)C)=C(N(C2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)[Si](C)(C)C(C)(C)C)N=C1N(C1CCOCC1)[Si](C)(C)C(C)(C)C6242.6Standard polar33892256
Spectra

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Gilteritinib 10V, Positive-QTOFsplash10-0udr-0000190000-7b069a2087876761e8fa2017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Gilteritinib 20V, Positive-QTOFsplash10-000i-1011490000-237a35174d04410794102017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Gilteritinib 40V, Positive-QTOFsplash10-000i-9461450000-7d41dbf77d437212b83c2017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Gilteritinib 10V, Negative-QTOFsplash10-0udi-1000090000-8b4d6f5c3858f01da2142017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Gilteritinib 20V, Negative-QTOFsplash10-0udl-5426390000-4395cf1348f801f0a6a92017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Gilteritinib 40V, Negative-QTOFsplash10-0udu-9772340000-a06c8dc53fc1abfecda02017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Gilteritinib 10V, Positive-QTOFsplash10-0udi-0000090000-76934d5d33b0d49d5e9e2021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Gilteritinib 20V, Positive-QTOFsplash10-000i-0000190000-8e1fd32c5193e62d9b722021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Gilteritinib 40V, Positive-QTOFsplash10-0159-3931580000-ffb7efbcfcf7155326402021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Gilteritinib 10V, Negative-QTOFsplash10-0udi-0000090000-949676c42707aa90f3aa2021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Gilteritinib 20V, Negative-QTOFsplash10-0udi-0000390000-31740be01a8beff5192c2021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Gilteritinib 40V, Negative-QTOFsplash10-0ukc-3245980000-981f76f06ec8e82622892021-10-12Wishart LabView Spectrum
Biological Properties
Cellular LocationsNot Available
Biospecimen Locations
  • Blood
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodDetected but not QuantifiedNot QuantifiedNot SpecifiedNot SpecifiedNormal details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDDB12141
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID32055842
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkGilteritinib
METLIN IDNot Available
PubChem CompoundNot Available
PDB IDNot Available
ChEBI ID145372
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Barupal DK, Fiehn O: Generating the Blood Exposome Database Using a Comprehensive Text Mining and Database Fusion Approach. Environ Health Perspect. 2019 Sep;127(9):97008. doi: 10.1289/EHP4713. Epub 2019 Sep 26. [PubMed:31557052 ]